Equites Radar

MDT · Medtronic plc.

Medical DevicesIrelandAnalyst view: Buy

$82.01

+0.15% last session

End-of-day data · updated 2026-07-25

Mildly bearish1 bullish · 3 bearish technical signals
Consensus: Buy (1.86 from 25 analysts)
To mean target: +19.3%

Market cap

$107B

Enterprise value

$127B

Trailing P/E

22.3

Forward P/E

13.0

Dividend yield

4.0%

Beta

0.58

Avg volume

10M

Employees

95K

2D change

1.46%

5D change

-0.10%

10D change

3.40%

30D change

4.27%

60D change

8.20%

MTD change

5.06%

YTD change

-11.88%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.86
Covering analysts25
Mean price target$97.84
Low price target$78.00
Upside to mean target+19.3%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)52.3
50-day MA$79.36
200-day MA$89.06
Price vs 50-day MA+3.3%
Price vs 200-day MA-7.9%
MACD histogram-0.11
Volume vs 3-month avg0.6×
52w low $73.0952w high $102.81

Analyst sentiment over time — MDT

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-28

Latest call per bank · past 12 months

UBS

Buy

$100

+21.9% vs price
▲ raised from $85.00Upgrade · 2026-07-28

Goldman Sachs

Neutral

$83.00

+1.2% vs price
▼ cut from $84.00Maintains · 2026-06-05

RBC Capital

Outperform

$118

+43.9% vs price
Reiterates · 2026-06-04

Wells Fargo

Overweight

$102

+24.4% vs price
▼ cut from $114Maintains · 2026-06-04

Citigroup

Buy

$110

+34.1% vs price
▼ cut from $117Maintains · 2026-04-07

Barclays

Overweight

$120

+46.3% vs price
▲ raised from $118Maintains · 2026-04-01

JP Morgan

Neutral

$100

+21.9% vs price
▼ cut from $105Maintains · 2026-02-18

Morgan Stanley

Overweight

$117

+42.7% vs price
▲ raised from $107Maintains · 2025-11-19

Recent rating actions

DateFirmActionRatingPrice target
2026-07-28UBSUpgradeNeutralBuy$85.00 $100
2026-07-10TD CowenMaintainsBuy$119 $100
2026-07-06Evercore ISI GroupMaintainsOutperform$106 $105
2026-06-17NeedhamReiteratesBuy$101
2026-06-05Goldman SachsMaintainsNeutral$84.00 $83.00
2026-06-05BernsteinMaintainsOutperform$112 $97.00
2026-06-04UBSMaintainsNeutral$90.00 $85.00
2026-06-04TD CowenReiteratesBuy$119

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-23

  • RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 3.3% above the 50-day MA ($79.36).
  • Price vs 200-day MA: Trading 7.9% below the 200-day MA ($89.06).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is negative (-0.11) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($73.09) and high ($102.81).

MDT Price Chart

Loading chart for MDT

Fundamentals

Revenue (TTM)$36B
EBITDA$10B
Free cash flow$5.0B
Operating cash flow$7.0B
Book value / share$38.64
Net debt / EBITDA2.0
WACC8.0%
Revenue growth10.00%
Earnings growth18.00%

About Medtronic plc.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

More in Medical Devices

Screen MDT against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.